Weiwei Sun

Title: Innovations of Weiwei Sun in Monoclonal Antibody Development

Introduction

Weiwei Sun is a notable inventor based in Suzhou, China. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. His work focuses on innovative methods and applications that have the potential to impact therapeutic treatments.

Latest Patents

Weiwei Sun holds a patent for a monoclonal antibody that binds to the TIGIT antigen. This invention includes a preparation method and its use in treating diseases such as tumors. The patent details a high-affinity monoclonal antibody or its derivatives that antagonistically inhibit the binding of TIGIT to its ligand, CD155. The patent also specifies the amino acid sequences of the complementarity-determining regions of both the light and heavy chain variable regions of the antibody. Furthermore, it outlines a humanization preparation method for the antibody, which can be utilized in pharmaceutical compositions or drug preparations.

Career Highlights

Weiwei Sun is associated with Acroimmune Biotech Co., Ltd., where he continues to advance his research and development efforts. His innovative work in monoclonal antibodies positions him as a key figure in the biotechnology sector.

Collaborations

Weiwei Sun collaborates with esteemed colleagues, including Qunmin Zhou and Zui Chen, who contribute to his research endeavors. Their combined expertise enhances the potential for groundbreaking discoveries in the field.

Conclusion

Weiwei Sun's contributions to monoclonal antibody research exemplify the innovative spirit of modern biotechnology. His patent on the TIGIT antigen binding antibody showcases the potential for new therapeutic approaches in treating complex diseases.